BANK OF AMERICA CORP /DE/ SEC Filings

Bank of America Corporation filed an 8-K on 16 Jul 2025 to report second-quarter 2025 results (Item 2.02) and furnish related investor materials (Item 7.01).

• Net income: $7.1 billion.
• Diluted EPS: $0.89.
• The detailed press release is filed as Exhibit 99.1 and is incorporated by reference.
• Investor presentation (Ex. 99.2) and supplemental data (Ex. 99.3) are furnished and available on the company website.
• An investor conference call and webcast will be held 16 Jul 2025 to discuss the results.

No other material transactions, guidance updates, or strategic initiatives were disclosed. All information in Items 2.02 and 7.01 is treated as filed or furnished per Exchange Act requirements.

Bank of America Corporation (BAC), through its subsidiary BofA Finance LLC, is marketing Market Linked Securities—Auto-Callable with Fixed Percentage Buffered Downside Principal at Risk Securities tied to the Russell 2000® Index. Key dates include a Pricing Date of 17 July 2025, Issue Date of 22 July 2025, and Maturity Date of 20 July 2028. The notes are issued in $1,000 denominations and may be automatically called if the index closes at or above the Starting Value on any annual Call Date, providing minimum Call Premiums of 9 %, 18 % and 27 % (exact rates set on pricing). If not called, investors receive:

• $1,000 if the Ending Value is between 90 % and 100 % of the Starting Value (10 % downside buffer).
• $1,000 minus 1:1 downside exposure if the Ending Value falls below 90 % of the Starting Value, exposing investors to up to a 90 % loss of principal.

The securities do not pay periodic interest and upside is capped at the Call Premiums. Initial estimated value is $904.25 – $964.25, below the $1,000 offer price, reflecting dealer compensation (up to 2.575 %) and hedging costs. Credit exposure rests on BofA Finance and is fully and unconditionally guaranteed by BAC. Risk disclosures highlight potential loss of principal, limited liquidity, conflicts of interest, small-cap index volatility, and uncertain tax treatment. Investors should review the preliminary pricing supplement, product supplement WF-1, prospectus supplement and prospectus before investing.